For the last several years, artificial intelligence in life sciences has largely lived in innovation labs and pilot programs—valuable but often disconnected from the workflows that actually drive regulatory approvals, market access, and clinical decision-making. In 2026, that changes. Our first prediction from MadeAi & CapeStart’s 2026 outlook, developed with insights from Angeline Dhas, Head…
